Early Efficacy Data from Phase 1b/2 Study of AVB500 in Combination with Standard Chemotherapy in Patients with Platinum Resistant Ovarian Cancer to be Presented HOUSTON , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been
CEO Jay Shepard to step down from his current role after a successor is appointed HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including
HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, today announced that company management will participate at the following upcoming investor
HOUSTON , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollment in Phase 1b Trial of AVB-500 in platinum-resistant ovarian cancer HOUSTON , July 31, 2019 (GLOBE NEWSWIRE) -- Aravive Inc.
AVB-500 demonstrates favorable safety profile and full suppression of circulating GAS6 in cancer patients HOUSTON , July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. ( Aravive ) (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, announced that the independent Data Monitoring Committtee (DMC)
HOUSTON , May 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
Data from Non-clinical Ovarian Cancer Study of AVB-500 and Proprietary GAS6 Biomarker Presented at the Society of Gynecologic Oncology’s 50th Annual Meeting HOUSTON , March 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that data
HOUSTON , March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: Event: Cowen and Company 39th Annual Health Care Conference Presentation Date &
HOUSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company focused on developing innovative therapies that target important survival pathways for cancer, announced recent corporate updates and financial results for the fourth quarter and
